Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

M.D. Anderson Cancer Center clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1102
Shown on this page
12
Current sort
Recently updated
Sponsor scope
M.D. Anderson Cancer Center
Additional filters apply within this sponsor.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this sponsor

These controls apply only within M.D. Anderson Cancer Center. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 781–792 of 1,102 matching trials for sponsor M.D. Anderson Cancer Center.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Counseling Sessions, Lab Session, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Saliva Test, Varenicline
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 30, 2026, 4:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity in Promoting Smoking Cessation in African Americans

NCT01915810
View directory record Official record
Conditions
Current Smoker, Healthy Subject
Interventions
Exercise Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Tobacco Cessation Counseling
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 29, 2026, 12:53 AM EDT
Recruiting Phase 2 Interventional

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

NCT01515527
View directory record Official record
Conditions
Leukemia
Interventions
Cladribine, Cytarabine, Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 29, 2026, 1:39 AM EDT
Active, not recruiting Phase 2 Interventional

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

NCT01352520
View directory record Official record
Conditions
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Cutaneous Lymphomas, Hematologic Disorder, Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma
Interventions
SGN-35
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 14, 2026, 6:05 AM EDT
Active, not recruiting Phase 2 Interventional

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

NCT01217931
View directory record Official record
Conditions
Kidney Cancer
Interventions
Bevacizumab, Everolimus, Pazopanib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Aug 2, 2026, 4:32 AM EDT
Active, not recruiting Phase 1 Interventional

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

NCT01087554
View directory record Official record
Conditions
Advanced Cancer
Interventions
Everolimus, Sirolimus, Temsirolimus, Vorinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 30, 2026, 8:54 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Interviewing for Physical Activity

NCT01008787
View directory record Official record
Conditions
Cancer
Interventions
Interview, PA Newsletter, Questionnaire, Training
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 10:41 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Susceptibility to Bladder Cancer

NCT00848289
View directory record Official record
Conditions
Bladder Cancer
Interventions
Interviews
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6,086 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 29, 2026, 1:02 AM EDT
Active, not recruiting Phase 2 Interventional

Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting

NCT00618553
View directory record Official record
Conditions
Lung Cancer
Interventions
Pulmonary Rehabilitation, Questionnaire
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Not yet recruiting Phase 2 Interventional

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

NCT07164469
View directory record Official record
Conditions
Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions
CD70.CAR NK Cells, Cyclophosphamide, Fludarabine, Rimiducid (AP1903)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 15, 2026, 2:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

NCT06066437
View directory record Official record
Conditions
Prostate Cancer
Interventions
Arm A: 177Lu rhPSMA-10.1, Arm B: 177Lu rhPSMA-10.1 plus Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Aug 2, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

NCT05464719
View directory record Official record
Conditions
Large B-cell Lymphoma, Lymphoma
Interventions
Loncastuximab Tesirine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Aug 2, 2026, 2:53 AM EDT

About this M.D. Anderson Cancer Center sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where M.D. Anderson Cancer Center is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within M.D. Anderson Cancer Center trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at MD Anderson Cancer Center in Houston, TX, or open the full search for M.D. Anderson Cancer Center.